Immutep Completes Recruitment of 2
nd line PD-1/PD-L1 refractory NSCLC Patients
in TACTI-002
• Last 2
nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and
safely dosed, completing recruitment of Stage 2 of Part B
• Total of 154 patients out of up to 183 patients (84%) now participating in the expanded trial, with
recruitment continuing for the expansion stage of Part A
• Further data expected to be reported in calendar year 2021 or early calendar year 2022
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory...
-
- There are more pages in this discussion • 264 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |